Medical News Today
Researchers at from the Harold C. Simmons Comprehensive Cancer Center
have found that the BRCA1 gene is required for the survival of blood
forming stem cells, which could explain why patients with BRCA1 mutations do not have an elevated risk for leukemia. The stem cells die before they have an opportunity to transform into a blood cancer.
"One of the great mysteries in cancer research is why inherited
mutations, such as those in BRCA1, cause cancer only in specific tissues
such as the breast and ovaries, rather than in all tissues. Our data
suggest a 'die or transform' hypothesis, which could explain this tissue
specificity," said Dr. Theodora Ross, Professor of Internal Medicine
and Director of the Cancer Genetics Program at UT Southwestern.
Additional data from this study suggest these patients may have a tougher time with the side effects of chemotherapy.
"Patients with certain BRCA1 mutations may be at a higher than expected
risk for serious complications during chemotherapy treatment," said Dr.
Ross, who holds the Jeanne Ann Plitt Professorship in Breast Cancer
Research and the H. Ben and Isabelle T. Decherd Chair in Internal
Medicine in Honor of Henry M. Winans, Sr., M.D. "If we confirm these
clinical findings in upcoming studies, giving patients preventative antibiotics or growth factors may be necessary to lower this increased risk of treatment side effects.".......
Article: Distinct Brca1 Mutations Differentially Reduce Hematopoietic Stem Cell Function, Victoria E. Mgbemena, Robert A.J. Signer, Ranjula Wijayatunge, Travis Laxson, Sean J. Morrison, Theodora S. Ross, Cell Reports, doi: 10.1016/j.celrep.2016.12.075, published 24 January 2017.
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.